News | November 15, 2022
Orchid Pharma reports positive EBIDTA in Q2
The company is focussed on increasing the capacity utilizations while controlling costs
The company is focussed on increasing the capacity utilizations while controlling costs
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Subscribe To Our Newsletter & Stay Updated
